Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 576-584

  Rolle, Cleo E ^a   Kanteti, Rajani ^a   Surati, Mosmi ^b   Nandi, Suvobroto ^a   Dhanasingh, Immanuel ^a   Yala, Soheil ^a   Tretiakova, Maria ^a   Arif, Qudsia ^a   Hembrough, Todd ^c   Brand, Toni M ^d   Wheeler, Deric L ^d   Husain, Aliya N ^a   Vokes, Everett E ^a   Bharti, Ajit ^e   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c OncoPlex Diagnostics   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; FIRTECAN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

CAMPTOTHECIN; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; TOPOISOMERASE I INHIBITORS;

EID: 84896287948     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0109     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10-29.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiolis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. (Pubitemid 46630948)
3. Minna J, Schiller J. In: Fauci AS, Braunwald Eugene, Kasper Dennis L, Hauser Stephen L, Longo Dan L, Jameson J. Larry, editors. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 551-62.
4. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801. (Pubitemid 29269249)
5. Janne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Sheperd FA, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002;95:1528-38.
6. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 1987;329:451-4. (Pubitemid 17128316)
7. Petersen I, Langreck H, Wolf G, Schwendel A, Psille R, Vogt P, et al. Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br J Cancer 1997;75:79-86. (Pubitemid 27007277)
8. Whang-Peng J, Bunn PAJr, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, et al. A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 1982;6:119-34.
9. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62. (Pubitemid 27268450)
10. Dooley S, Wundrack I, Blin N, Welter C. Coexpression pattern of c-myc associated genes in a small cell lung cancer cell line with high steady state c-myc transcription. Biochem Biophys Res Commun 1995;213:789-95.
11. Levin NA, Brzoska P, Gupta N, Minna JD, Gray JW, Christman MF. Identification of frequent novel genetic alterations in small cell lung carcinoma. Cancer Res 1994;54:5086-91. (Pubitemid 24313481)
12. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994;145:1036-40. (Pubitemid 24345651)
13. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8. (Pubitemid 24042076)
14. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207-17. (Pubitemid 28108759)
15. Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J 2004;4:589-604.
16. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81. (Pubitemid 37255174)
17. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-7. (Pubitemid 38018071)
18. Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RLJr Imatinibmesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 2004;10:3528-34. (Pubitemid 38685463)
19. Birchmeier C, Birchmeier W, Gherardi E, VandeWoude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
20. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, VandeCoude GF, et al. Identification of the hepatocyte growth factor receptor as the MET proto-oncogene product. Science 1991;251:802-4. (Pubitemid 21926175)
21. Maulik G, Madhiwala P, Brooks S, Ma PC, Kjima T, Tibaldi EV, et al. Activated MET signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6:539-53. (Pubitemid 44149770)
22. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16. (Pubitemid 351767118)
23. Kim ES, Salgia R. METpathway as a therapeutic target. J Thorac Oncol 2009;4:444-7.
24. Peruzzi B, Bottaro DP. Targeting the MET signaling pathway in cancer. Clin Cancer Res 2006;12:3657-60. (Pubitemid 44000247)
25. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88. (Pubitemid 40270177)
26. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
27. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-7.
28. Chhatriwala H, Jafri N, Salgia R. A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther 2006;5:1600-7.
29. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Suguira T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
30. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
31. Kanteti R, Yala S, Ferguson MK, Salgia R. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol 2009;28:89-98.
32. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989;49:58-62. (Pubitemid 19024407)
33. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the MET receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71.
34. Nusrat A, Parkos CA, Bacarra AE, Godowski PJ, Delp-Archer C, Rosen EM, et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of MET receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest 1994;93:2056-65.
35. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007;97:368-77. (Pubitemid 47196754)
36. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9. (Pubitemid 37139865)